Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?

被引：0

作者：

Park, Jihye ^{[1
,2
]}

Cheon, Jae Hee ^{[1
,2
,3
]}

机构：

[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea

[2] Yonsei Univ, Coll Med, Inst Gastroenterol, Seoul, South Korea

[3] Yonsei Univ, Coll Med, Brain Korea 21 PLUS Project Med Sci, Seoul, South Korea

来源：

GUT AND LIVER | 2021年 / 15卷 / 05期

关键词：

INFLIXIMAB; REMISSION;

D O I：

10.5009/gnl210345

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

See "Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-alpha Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study" by Joo Hye Song, et al. on page 752, Vol. 15, No. 5, 2021

引用

页码：641 / 642

页数：2

共 7 条

[1] Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn's disease: 3-year results from a real-world study [J].

Hisamatsu, Tadakazu ;

Suzuki, Yasuo ;

Kobayashi, Mariko ;

Hagiwara, Takashi ;

Kawaberi, Takeshi ;

Ogata, Haruhiko ;

Matsui, Toshiyuki ;

Watanabe, Mamoru ;

Hibi, Toshifumi .

INTESTINAL RESEARCH, 2021, 19 (04) :408-418

[2] Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial [J].

Kobayashi, Taku ;

Motoya, Satoshi ;

Nakamura, Shiro ;

Yamamoto, Takayuki ;

Nagahori, Masakazu ;

Tanaka, Shinji ;

Hisamatsu, Tadakazu ;

Hirai, Fumihito ;

Nakase, Hiroshi ;

Watanabe, Kenji ;

Matsumoto, Takayuki ;

Tanaka, Masanori ;

Abe, Takayuki ;

Suzuki, Yasuo ;

Watanabe, Mamoru ;

Hibi, Toshifumi .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (06) :429-437

[3] Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped [J].

Louis, Edouard ;

Mary, Jean-Yves ;

Vernier-Massouille, Gwenola ;

Grimaud, Jean-Charles ;

Bouhnik, Yoram ;

Laharie, David ;

Dupas, Jean-Louis ;

Pillant, Helene ;

Picon, Laurence ;

Veyrac, Michel ;

Flamant, Mathurin ;

Savoye, Guillaume ;

Jian, Raymond ;

Devos, Martine ;

Porcher, Raphael ;

Paintaud, Gilles ;

Piver, Eric ;

Colombel, Jean-Frederic ;

Lemann, Marc .

GASTROENTEROLOGY, 2012, 142 (01) :63-U201

[4] Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study [J].

Ogata, Haruhiko ;

Hagiwara, Takashi ;

Kawaberi, Takeshi ;

Kobayashi, Mariko ;

Hibi, Toshifumi .

INTESTINAL RESEARCH, 2021, 19 (04) :419-429

[5] Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy [J].

Phan, Hiep ;

Weideman, Rick A. ;

Cipher, Daisha J. ;

Feagins, Linda A. .

INTESTINAL RESEARCH, 2020, 18 (03) :282-288

[6] Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study [J].

Song, Joo Hye ;

Kang, Eun Ae ;

Park, Soo-Kyung ;

Hong, Sung Noh ;

Kim, You Sun ;

Bang, Ki Bae ;

Kim, Kyeong Ok ;

Lee, Hong Sub ;

Kang, Sang-Bum ;

Shin, Seung Yong ;

Song, Eun Mi ;

Im, Jong Pil ;

Choi, Chang Hwan .

GUT AND LIVER, 2021, 15 (05) :752-762

[7] Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease? [J].

Theodoraki, Eirini ;

Orfanoudaki, Eleni ;

Foteinogiannopoulou, Kalliopi ;

Legaki, Evangelia ;

Gazouli, Maria ;

Koutroubakis, Ioannis E. .

INTESTINAL RESEARCH, 2021, 19 (04) :461-467

← 1 →